Innnogenetics NV (EBR:INNX) will release the half year earnings results for 2008 on Monday, August 18 after the closing of the stock exchange. The financial results will be posted on the company’s website at innogenetics.com.
Innogenetics NV is a Belgium-based biopharmaceutical company. Innogenetics specializes in the discovery, development, manufacture, marketing and sale of specialty diagnostics and therapeutic vaccines. The specialty diagnostics division focuses on distribution, co-development, and out-licensing in the field of HCV genotyping, HIV-1 group O, and bacteriology. It also develops applications for innate immunity/MBL2 genotyping in different disease fields. The division is active in the neurodegeneration market, developing tests for Alzheimer's disease. The therapeutic vaccines division focuses on vaccines for infectious diseases, including hepatitis B and C.
Innogenetics has subsidiaries in France, Germany, Italy, Brazil and the United States, which are all engaged in the distribution and sale of Innogenetics products. Its subsidiaries XCELLentis NV and CellTran Ltd. are both engaged in the development and sale of wound care products. Innogenetics NV is headquartered in Ghent.
Read more Business News on The Global Market Directory.
About The Global Market Directory (TheGMD)
TheGMD provides an online global directory listing featuring public companies, stock brokers, brokerage firms and individuals. The GMD provides profiles for Brokerage Firms, Stock Brokers and Individuals in addition to Public Companies.
The GMD is a division of TransWorldNews, Inc. Companies can utilize the TransWorldNews press release distribution services and have all news releases attached to their GMD profile.
Create your profile on The Global Market Directory.
